Ipilimumab. CTLA-4 is an immunomodulatory molecule that acts as a negative regulator of T-cell-mediated immune responses. Ipilimumab is a humanized IgG1 anti-CTLA-4 monoclonal antibody that is ...

Ipilimumab is generally well tolerated but can be associated with a host of novel side effects, presumably due to the immune system activation by CTLA-4 blockade. Collectively the spectrum of side ...

version 2.0 The approval in 2011 by the US Food and Drug Administration of the first cytotoxic T lymphocyte protein 4 (CTLA-4) antagonistic antibody, Bristol-Myers Squibb’s ipilimumab ...

and the ipilimumab/CTLA-4 drug-target complex. In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) and SmartPharm ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...